We are live on
!
Find out more
FGP
Foyston, Gordon, & Payne Portfolio holdings
AUM
$434M
1-Year Est. Return
9.09%
This Fund
S&P 500
This Quarter
Est. Return
+1.05%
1 Year Est. Return
+9.09%
3 Year Est. Return
+56.86%
5 Year Est. Return
+84.63%
10 Year Est. Return
+238.52%
AUM
$576M
AUM Growth
+$112M
(+24%)
Cap. Flow
+$110M
Cap. Flow
% of AUM
19.04%
Top 10 Holdings %
Top 10 Hldgs %
51.94%
Holding
67
New
3
Increased
30
Reduced
21
Closed
4
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Johnson & Johnson
JNJ
|
+$27.5M |
| 2 |
UnitedHealth
UNH
|
+$23.9M |
| 3 |
Medtronic
MDT
|
+$13.4M |
| 4 |
Novartis
NVS
|
+$6.8M |
| 5 |
Microsoft
MSFT
|
+$6.22M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
COL
Rockwell Collins
COL
|
+$12.1M |
| 2 |
Bunge Global
BG
|
+$3.79M |
| 3 |
Pfizer
PFE
|
+$2.92M |
| 4 |
BHI
Baker Hughes
BHI
|
+$2.64M |
| 5 |
Johnson Controls International
JCI
|
+$2.42M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 36.3% |
| 2 | Technology | 18.5% |
| 3 | Industrials | 13.86% |
| 4 | Financials | 12.79% |
| 5 | Consumer Staples | 7.18% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Telefônica Brasil
VIV
$22.5B
| $1.36M | 0.24% |
85,682
-5,800
| -6% | -$88K |
|
52
Becton Dickinson
BDX
$43.8B
| $1.23M | 0.21% |
6,458
| – | – |
|
53
Sanofi
SNY
$105B
| $1.19M | 0.21% |
23,850
| – | – |
|
54
AbbVie
ABBV
$454B
| $1.09M | 0.19% |
12,275
| – | – |
|
55
Abbott
ABT
$182B
| $685K | 0.12% |
12,843
| – | – |
|
56
Sasol
SSL
$7.34B
| $685K | 0.12% |
24,869
-2,300
| -8% | -$67.7K |
|
57
3M
MMM
$91.9B
| $559K | 0.1% |
3,186
-706
| -18% | -$122K |
|
58
ExxonMobil
XOM
$642B
| $504K | 0.09% |
6,145
-1,392
| -18% | -$111K |
|
59
Procter & Gamble
PG
$346B
| $489K | 0.08% |
5,377
-1,500
| -22% | -$137K |
|
|
CHL
60
DELISTED
China Mobile Limited
CHL
| $469K | 0.08% |
9,283
-700
| -7% | -$37.3K |
|
|
PTR
61
DELISTED
PETROCHINA COMPANY LIMITED ADS (REP 100 H SHARES)
PTR
| $454K | 0.08% |
7,082
-300
| -4% | -$19K |
|
62
IBM
IBM
$204B
| $241K | 0.04% |
+1,734
| New | +$242K |
|
63
JPMorgan Chase
JPM
$947B
| $216K | 0.04% |
+2,266
| New | +$209K |
|
|
64
Bunge Global
BG
$22.8B
| – | – |
-50,806
| Closed | -$3.79M |
|
65
Verizon
VZ
$198B
| – | – |
-37,269
| Closed | -$1.66M |
|
|
COL
66
DELISTED
Rockwell Collins
COL
| – | – |
-115,616
| Closed | -$12.1M |
|
|
BHI
67
DELISTED
Baker Hughes
BHI
| – | – |
-48,385
| Closed | -$2.64M |
|
Similar funds
HCM
GS
IA
PAMS
SSWG
JWM
GDS
GPP
Foyston, Gordon, & Payne's Q3 2017 Portfolio in Review
As of Q3 2017, Foyston, Gordon, & Payne held 67 positions worth $576M, up 24% from $464M the previous quarter. Its ten largest holdings account for 52% of the portfolio.
Foyston, Gordon, & Payne deployed $110M of net new capital in Q3 2017, opening 3 new positions and adding to 30 existing holdings. Its largest new stake was Baker Hughes: 140,613 shares worth $5.15M.
By sector, the portfolio is most concentrated in Healthcare at 36% of assets, up from 29% a quarter earlier, followed by Technology and Industrials.
On the sell side, the largest reduction was Pfizer, an estimated $2.92M trimmed.
- Foyston, Gordon, & Payne's largest Q3 2017 buy was Baker Hughes: 140,613 shares worth $5.15M.
- Foyston, Gordon, & Payne added most to Johnson & Johnson in Q3 2017, an estimated $27.5M increase.
- Foyston, Gordon, & Payne's biggest Q3 2017 reduction was Pfizer, cutting an estimated $2.92M.
- Foyston, Gordon, & Payne fully exited Rockwell Collins in Q3 2017, selling an estimated $12.1M.
- Foyston, Gordon, & Payne's ten largest holdings make up 52% of its $576M portfolio in Q3 2017.
- Foyston, Gordon, & Payne opened 3 new positions and closed 4 in Q3 2017.
- Foyston, Gordon, & Payne's portfolio value rose 24% quarter-over-quarter to $576M.
Based on Foyston, Gordon, & Payne's 13F filing for Q3 2017, filed 14 Nov 2017.